menu
    • menu
    PHARMACOMPASS
    PHARMACOMPASS

    Grow Your Pharma Business Digitally
    X
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Gilead, US government resolve long-running HIV patent dispute

    PRESS RELEASE

    Gilead`s Lenacapavir Shows 96% HIV Infection Reduction In Phase 3

    BUSINESSWIRE

    Gilead To Present HIV Research Progress At AIDS 2024

    BUSINESSWIRE

    Gilead`s long-acting HIV drug superior to daily pill Truvada in study

    REUTERS

    Apotex`s Generic Emtricitabine;TAF Receives Approval in the U.S.

    FDA

    FDA Approves Biktarvy® Label Update With Data for Pregnant Adults With HIV

    BUSINESSWIRE

    Gilead Sciences Announces First Quarter 2024 Financial Results

    PRESS RELEASE

    Laurus Labs` Generic Bictegravir, Emtricitabine, Tenofovir Alafenamide Receives Approval in the U.S.

    FDA

    FDA Confirms Paragraph IV Patent Litigation for Bictegravir Sodium, Emtricitabine and Tenofovir Alafenamide Fumarate Tablets

    FDA

    Gilead Wins HIV Patent Suit, Nabs Oncology and Inflammation Startup

    BIOSPACE

    Gilead, US square off in billion-dollar HIV drug patent trial

    REUTERS

    ViiV, Gilead row escalates to feds after self-regulation fails

    FIERCE PHARMA

    Aurobindo`s Generic Emtricitabine, Tenofovir Disoproxil Fumarate Receives Approval in the U.S.

    FDA

    GSK`s ViiV says its long-acting HIV shot as effective as Gilead`s daily pill

    REUTERS

    Lupin gets USFDA nod for Dolutegravir, Emtricitabine and Tenofovir tablets

    ECONOMIC TIMES

    Lupin`s Generic Dolutegravir Sodium, Emtricitabine and Tenofovir Alafenamide Receives Approval in the U.S.

    FDA

    Aurobindo`s Generic Emtricitabine and Tenofovir Alafenamide Receives Approval in the U.S.

    FDA

    FDA Confirms Paragraph IV Patent Litigation for Emtricitabine and Tenofovir Alafenamide Fumarate Tablets

    FDA

    Federal claims court rules in favor of Gilead in CDC Truvada patent case

    ENDPTS

    Gilead receives EC marketing authorisation for HIV treatment in children

    PHARMACEUTICAL-TECHNOLOGY

    Gilead Presents Real-World Evidence Reinforcing the Use of Biktarvy

    BUSINESSWIRE

    Cipla`s Generic Tenofovir Alafenamide, Rilpivirine, Emtricitabine Receives Approval in the U.S.

    FDA

    My Biggest Worry About Gilead Sciences

    FOOL

    Gilead can`t escape antitrust suit centered on Cipla deal

    FIERCEPHARMA

    Gilead trumpets a Biktarvy win in HIV, hepatitis B co-infection

    FIERCEPHARMA

    Gilead says network of suppliers & distributors sold fake versions of HIV meds

    ENDPTS

    FDA Approves Expanded Indication of Gilead’s Biktarvy for HIV-1 in Pediatrics

    BUSINESSWIRE

    Hetero Labs`s Generic Emtricitabine; Tenofovir Receives Approval in the US

    FDA

    FDA Confirms Paragraph IV Patent Challenge of Symtuza 210455 (Darunavir, Cobicistat, Emtricitabine, Tenofovir Alefenamide) 80mg/ 150mg/ 200mg/ 10mg tablets

    FDA

    Gilead, Merck and others slapped with `pay-for-delay` lawsuits

    FIERCEPHARMA

    Macleods Pharms`s Generic Efavirenz; Emtricitabine; Tenofovir Disoproxil Fumarate Receives Approval In US

    FDA

    Macleods Pharms`s Generic Efavirenz;Emtricitabine;Tenofovir Disoproxil Fumarate Receives Approval In US

    FDA

    Lupin`s Generic Emtricitabine; Tenofovir DF Receives Approval In US

    FDA

    Apotex`s Generic Emtricitabine Receives Approval in US

    FDA

    Apotex`s Generic Emtricitabine; Tenofovir; Disoproxil Receives Approval in US

    FDA

    Biktarvy® Demonstrates High Efficacy and Durable Viral Suppression

    BUSINESSWIRE

    Strides receives USFDA approval Emtricitabine & Tenofovir Disoproxil Fumarate

    BUSINESS-STANDARD

    Gilead Canada Announces Notice of Compliance for DESCOVY®

    BUSINESSWIRE

    GSK`s long-acting HIV PrEP drug tops Gilead`s Truvada in women

    FIERCE PHARMA

    Gilead`s Truvada faces Teva generic amid switching effort

    FIERCE PHARMA

    Common HIV drugs increase a type of immunity in the gut

    NEWSWIRE

    China National Medical Products Administration Approves Truvada® (PrEP)

    BUSINESSWIRE

    UK marketing police slam Gilead for misleading Biktarvy promos

    FIERCE PHARMA

    ViiV Healthcare Announces Superior Efficacy of Investig, Long-Acting Injectable

    BUSINESSWIRE

    At 83, AIDS activist Larry Kramer isn’t done ripping into his foes in pharma

    STATNEWS

    GSK touts long-acting PrEP win against Gilead`s Truvada

    FIERCE PHARMA

    ViiV HIV prevention trial stopped early on efficacy

    PHARMA TIMES

    Gilead sues U.S.claiming it ‘secretly’ obtained patents HIV research to Truvada

    STATNEWS

    The top 10 drugs losing U.S. exclusivity in 2020

    FIERCE PHARMA

    Study shows newer anti-HIV drugs safest, most effective during pregnancy

    PHARMABIZ

    Gilead Presents 96-week DISCOVER Trial Data

    BUSINESS WIRE

    Gilead`s Descovy not worth the higher price

    FIERCE PHARMA

    Zydus receives final approval from the USFDA for Emtricitabine & Tenofovir

    EQUITYBULLS

    Misleading ads turn people away from HIV-prevention meds

    IFPRESS

    DoP rejects Emcure Pharma`s review application against NPPA`s price

    PHARMABIZ

    The chemical revolution of central Europe

    CEN

    FDA Confirms Paragraph IV Patent Challenge of Descovy 208215 (Emtricitabine and Tenofovir Alafenamide Fumarate) Tablets

    FDA

    FDA Confirms Paragraph IV Patent Challenge of Odefsey 208351 (Emtricitabine, Rilpivirine Hydrochloride and Tenofovir Alafenamide Fumarate )Tablets

    FDA

    Pfizer, BMS, AbbVie and others raise prices to ring in 2020

    FIERCE PHARMA

    Facebook yanks HIV lawsuit ads after protest, fact check

    FIERCE PHARMA

    Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.